INVESTER I CURIS MED ENDAVU: Køb Curis ($CRIS) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Curis, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Curis Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of human cancers. The company concentrates on first-in-class and differentiated drugs, primarily small-molecule inhibitors that target key signaling pathways involved in hematologic malignancies and solid tumors. Its lead candidate, emavusertib (CA-4948), is an orally available inhibitor of IRAK4 and FLT3 being evaluated in Phase 1/2 studies for conditions such as non-Hodgkin lymphomas, primary central nervous system lymphoma, acute myeloid leukemia, myelodysplastic syndromes, and chronic lymphocytic leukemia, often in combination with BTK inhibitors. Curis also has additional clinical programs, including CI-8993, a monoclonal antibody targeting immune regulation, and other oncology assets within its pipeline. The company collaborates with partners such as Aurigene Discovery Technologies and the National Cancer Institute to advance its research and clinical development. Headquartered in Lexington, Massachusetts, Curis Inc. plays a specialized role in the oncology market by advancing targeted cancer therapies designed to improve patient outcomes.